Dr Switzer founded MitoGenetics as an Iowa LLC in 2010. It is focused on the research, development and refinement of biomedical technology, in particular primordial energy control and signaling systems regulating mitochondrial metabolism.
Dr. Bill Switzer, a retired research veterinarian from Iowa State University, focused Mitogenetics attention on primordial signaling that provides beneficial effects on the functioning of cells given its ancient status.
MitoGenetics entered into a collaboration agreement with the State University of New York in Old Westbury to determine if novel bio-medically active compounds exist affecting primordial systems and to conduct research into the medicinal properties of opioid compounds since its Neuroscience Research Institute was engaged in this type of research for over 35 years. Specifically, to focus the research on mitochondrial diseases since this organelle is common in eukaryotic cells.
Processes were developed to isolate and purify the known compound to make it available for additional research and trials. The goal is to naturally control mitochondrial energy with compounds that can be used for medicinal remedies.
In 2015, MitoGenetics, in partnership with the State University of New York, hired the original team of scientists to help accelerate the innovation that will lead to major breakthroughs in therapeutic strategies for mitochondrial dysfunction.